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1.1 Intention of the presented work  
Gestational diabetes mellitus (GDM) is one of the most common complications in 
pregnancies. Presently, 3-5% up to 14% of the pregnant women are affected, dependent on 
the ethnical group investigated. Actual estimations suggest that the prevalence of GDM will 
significantly increase in the near future due to the rising rate of obesity and glucose 
intolerance in young women in industrialized countries. Optimal medical care has to be 
provided to avoid short and long term sequelae for the fetus and the mother. On the other side 
there is clearly a need for a concept of management of GDM which guarantees a reasonable 
balance of efficacy and costs. For more than two decades there is an ongoing discussion about 
the optimal management strategy in pregnancies with GDM. 
In 2001 the guidelines for diagnosis and therapy of GDM in Germany had been 
modified based on the suggestions of an expert panel of the German Society of Obstetrics and 
Gynecology (DGGG) and the German Diabetes Association (DDG). The major goal of this 
attempt was an adaptation of the German guidelines to the international standard. Although a 
concept was developed that considers all available data well as clinical experience and best 
practicability, several questions remain. There is controversy about the best glycemic 
thresholds for the diagnosis of GDM as well as the optimal glucose targets during pregnancy. 
While intensive glucose control in women with GDM has been proven to reduce neonatal 
morbidity, the rates of accelerated growth (macrosomia) and it's associated complications are 
still elevated, as compared to the normal obstetrical population. Thus, do we have to modify 
our criteria for insulin therapy to reduce morbidity? In studies that target to reduce 
macrosomia, intensive insulin therapy was required in the majority of the women. This does 
not seem reasonable. How can we identify pregnancies with a high risk for neonatal 
morbidity? Are the maternal glucose values reliable predictors for morbidity or do we have to 
include other parameters to improve the outcome?  Do we really have to monitor intensively 
the glucose metabolism in all woman with GDM? 
 
This manuscript constitutes a part of the ongoing attempt to find for answers to these 
questions. It summarizes the quintessence of almost 10 years of clinical research in the field 
of gestational diabetes. Our research covers various aspects of pregnancies complicated by 
diabetes including congenital anomalies, maternal and fetal predictors for neonatal morbidity, 
predictors for postpartum diabetes after GDM and the influence of contraception on the 
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development of diabetes after pregnancies with GDM and. Based on the clinical experience in 
our Diabetic Prenatal Care Clinic we became more and more aware of an urgent need to 
modify the principles of the management of GDM. When looking at the outcome parameters 
it seemed that several of the women were under-treated, while others were over-treated when 
therapy was based solely on strict glycemic control. 
 
In the first part, based on own data and several studies by others this thesis assesses 
the importance of maternal glucose values to predict adverse neonatal outcome. In the second 
part, the results of intervention trials done by our group will be presented that investigated a 
modified management combining maternal and fetal criteria to guide therapy. The advantage 
of this approach will be demonstrated that provides the opportunity to adjust the intensity of 
surveillance and therapy based on antenatal risk assessment.  
1. Introduction  6 
 
1.2. Gestational diabetes 
 
1.2.1. Epidemiology and pathophysiology 
GDM is defined as glucose intolerance of varying degrees of severity with onset or 
first recognition during pregnancy 1. The prevalence of GDM is dependent on the prevalence 
of type 2 diabetes in the given population and varies from 1-14% with 2-5% being the most 
common figure 2-4. Risk factors for GDM are increasing age, positive family history of 
diabetes, increasing obesity and descent from selected ethnic groups with high prevalence of 
diabetes. 
Pregnancy is associated with profound hormonal changes that have a direct effect on 
the carbohydrate tolerance. In the 1st trimester, progesterone and estrogen rise but 
counterbalance regarding their insulin action. Once the 2nd trimester is entered, human 
placental lactogen (HPL) , cortisol and prolactin increases, causing decreased phosphorylation 
of the insulin receptor substrate-1 5 and profound insulin resistance 6, 7. In most women, 
pancreatic insulin secretion adapts to this need, but in those with underlying beta-cell defects, 
hyperglycemia ensues. Women typically return to euglycemia postpartum but defects in 
insulin secretion and action are still evident. 8 
 
1.2.2  Morbidity 
Maternal morbidity 
Maternal hyperglycemia in GDM is rarely severe enough to cause concern for the 
mother. Women with GDM are more likely to develop hypertensive disorders than women 
without GDM which might be partly related to the underlying risk factors for GDM (obesity, 
increasing age). There is a higher risk of vaginal and urinary infections causing preterm labor. 
At delivery, neonatal macrosomia results in a higher risk of C-section and birth traumata for 
mother and child. A pregnancy with GDM indicates a maternal long-term risk of diabetes in 
later life. Approximately 10-15% of the women remain diabetic postpartum 9, 10, the 
cumulative risk is approximately 50% for diabetes and 75 % for any other impairment of 
glucose intolerance within 10 years after the index pregnancy. 10-13  
 
Fetal and neonatal morbidity 
Fetal  hyperinsulinism secondary to an excessive supply of substrate due to maternal 
hyperglycemia (Pederson hypothesis) 14 is the underlying cause for all short-and long term 
complications of GDM. The primary perinatal concern in GDM remains the excessive fetal 
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growth (fig 1). Macrosomia is significantly more common in pregnancies with GDM even 
when GDM is treated according to standard recommendations. Fat accumulation tends to be 
truncal with a larger shoulder circumference which leads to an increased risk for 
cephalopelvic disproportion and shoulder dystocia. 15 Other significant acute neonatal 
morbidities include hypoglycemia, hyperbilirubinemia, hypocalcemia and polycthemia. 
 
 
Figure 1: Macrosomic newborn with diabetic fetopathy 
 
The infant of women with GDM inherits an increased susceptibility for glucose 
intolerance not only due to genetic disposition but due to the exposure to hyperglycemia in 
utero. Studies in Pima Indians demonstrated that children from the same mother who were 
born after the mother developed diabetes were more obese and more likely to have insulin 
resistance 16. Numerous studies support an increased risk for obesity in the offspring. 17, 18 
 
1.2.3 Diagnostic management 
There is a lively ongoing discussion about the diagnostic procedure for detection of 
GDM. The major controversies exist regarding universal screening versus diagnostic limited 
to women with risk factors and the diagnostic criteria for GDM. It would exceed the capacity 
of this text to go into the details of this discussion. The following presentation will be limited 
to the major issues of the current recommendations valid for Germany 19 which represent a 
modified version of the Recommendations of the Fourth International Workshop Conference 
on GDM. 1 
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Screening for GDM should be performed in every woman with 24-28 weeks of 
gestation. The diagnosis of GDM is based on the results of an oral glucose tolerance test 
(oGTT). The evaluation for GDM may be done in one or two steps. The one - step procedure 
requires a complete 75 g oGTT in all women. When two or more glucose values exceed the 
glycemic thresholds of fasting 90mg/dl, 180 mg/dl after 1 hour and 155 mg/dl after two hours, 
the criteria for GDM are met.20 The two-step procedure uses a 50 g glucose load (glucose 
challenge test) as selection criteria for the oGTT; it may be applied without regard to the time 
of day or last meal.  The diagnostic oGTT is reserved for women with glucose values above 
140 mg/dl in the screening test. When performed between 24-28 weeks of gestation, the 
screening test has a sensitivity of 80% at a 140 mg/dl cut point 1. Women with high-risk for 
GDM should be tested as soon as feasible and testing should be repeated at 24-28 weeks if 
GDM is not diagnosed. The cutoff values for the oGTT are derived from the original data 
from O’Sullivan from 1964 evaluating an increased risk for development of type 2 diabetes of 















Diagnostic procedure for GDM  
 
In contrast to the recommendations of the German Diabetes Association, currently (up 
to spring 2003) the German health system covers only a diagnostic for GDM in women with 
risk factors for GDM following the one-step procedure. About 50% of the women with GDM 
are missed by this selective testing. 2 Thus in this text, all presented studies which had been 
 
50 g challenge test 
> 140 mg/dl 
75 g oGTT
Risk factors 
Fasting  > 90 mg/dl 
1 hour  > 180 mg/dl 
2 hours > 155 mg/dl 
1st trimester testing 
   24-28 weeks of gestation 
Gestational diabetes 
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performed in Germany, are based on a population of women with GDM who were identified 
by selective testing. Additionally in the time period of the studies, the diagnosis of GDM was 
based on the O’Sullivan criteria (90/165/145 mg/dl) in most institutions in Germany. 
 
1.2.4  Therapy 
Antepartum treatment of women with GDM should be focused on the prevention of 
fetal complications. Dietary education is the first step in the treatment for GDM. The 
nutritional prescription should provide the caloric needs for pregnant women of 30 kcal per 
kilogram of actual body weight. The total intake should be reduced to 25 kcal for overweight 
women. Self monitoring of blood glucose is superior to less frequent measurements in the 
clinic. The recommended frequency of the glucose profiles consisting of 3 pre-and 3 
postprandial measurements varies between twice per week or daily. Glycemic goals during 
pregnancy are fasting values < 90 mg/dl, 1 hour postprandial < 140 mg/dl and 2 hour values < 
120 mg/dl. 19 In women who fail to achieve or maintain normoglycemia additional insulin 
therapy is recommended. Physical activity after meals increases glucose consumption and 
insulin sensitivity and it had been shown that in women with GDM insulin therapy could be 
avoided by a strict exercise protocol. 22 
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2. Own contributions  
 
2.1.  The influence of maternal glycemia on embryogenesis 
2.1.1  Introduction and summary  
Preexisting diabetes is a well known risk factor for congenital anomalies since 
maternal hyperglycemia during time of embryogenesis has a teratogenic effect of the 
development of the embryo. 23-28 Data from animal and clinical studies have demonstrated a 
correlation of the degree of maternal hyperglycemia during early pregnancy and the 
occurrence of malformations in the embryo. 29-31 Preconceptional care and optimizing of 
maternal glucose control can reduce the rate of anomalies to the level of the normal 
population. 27, 32, 33 In women with preexisting diabetes, a great body of data is available to 
assess the risk for diabetes based on the level of maternal glucose values. Congenital 
anomalies typical for diabetes affect primarily the heart, central nervous system, kidneys and 
the axial skeleton.  
 
Figure 3: Newborn with caudal regression syndrome - the most specific but rare congenital 
anomaly in pregnancies complicated by diabetes (from Smith's Recognizable Patterns of 
Human Malformation )  
 
Disturbance of fetal development causing these disorders must occur during the first 8 
weeks of pregnancy. Thus, GDM is not considered as risk factor for congenital malformations 
because it typically develops not before the late second trimester coincident with the 
decreasing insulin sensitivity at this time. But the definition of GDM as any glucose 
intolerance diagnosed first in pregnancy, comprises a wide range of metabolic 
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decompensation - from mild intolerance to overt hyperglycemia. It can be speculated that 
women with severe hyperglycemia at time of diagnosis of GDM might have had 
hyperglycemia in early pregnancy high enough to impart a risk for malformation to their 
children. So far, there had been very few data to quantify the risk of malformations in these 
heterogeneous population of women with GDM.  
 
•  Congenital malformations in offspring of women with GDM 
Our study aimed to determine the incidence of congenital anomalies in women with 
hyperglycemia diagnosed first in pregnancy and to identify clinical predictors for an increased 
risk for anomalies. A total of 3743 infants of mothers with GDM who attended the Diabetic 
Clinic of the Los Angeles County-University of Southern California Women’s and Children’s 
Hospital between 1987 and 1995 could be analyzed. Infants with genetic syndromes and 
aneuploidy were excluded. The incidence of was 2.9% for major congenital and 2.4% for 
minor anomalies. There was no difference in maternal historical or glycemic parameters 
between mothers of pregnancies with normal infants and infants with minor anomalies thus 
we combined them for the further analysis. The multivariate analysis revealed that the fasting 
glucose concentration at time of diagnosis was the only independent predictor (Odds ratio 
1.13 for each 10 mg/dl increase, 95% CI 1.08-1.16) for major malformations. The fasting 
glucose is an easy accessible clinical parameter since it is part of the diagnostic procedure. 
Thus we examined if there is a threshold glucose value for an increased risk. The population 
was divided into subgroups according their fasting glucose values using strata of 20 or 40 
mg/dl respectively. There was an abrupt increase in the risk for major congenital anomalies at 
a serum glucose concentration > 120 mg/dl and again at >260 mg/dl (table 1). 
 
Table 1: Rate of and odds ratio for the risk of major congenital malformations in a population 
of women with hyperglycemia diagnosed first in pregnancy 
 Total population Subgroup with normal  
oGTT 1- 4 month postpartum 
Fasting glucose (mg/dl) Rate OR (95%CI) Rate OR (95%CI) 
< 120  62 (2%) 1.0 22 (1.7%) 1.0 
121-260 39 (5%) 2.6* (1.7 - 3.8) 8 (3.7%) 2.1* (1.1-4.82) 
> 260 7 (30%) 20.5* (8.5-50.7) 0  
* p< 0.05 
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The majority of our study population belonged to the ethnic group of Mexican-American who 
are characterized by a high degree of glucose intolerance due to insulin resistance.  To 
exclude that our results were valid only for women with presumably undiagnosed preexisting 
type 2 diabetes, we repeat the analysis in a subgroup of women with normal oGTT (n= 1600) 
1- 4 month postpartum. We identified the same cut-off at 120 mg/dl but there was no case of 
fasting glucose  > 260 mg/dl in this subgroup. 
 
• Patterns of congenital anomalies and their relationship to initial maternal  hyperglycemia 
In pregnancies with type 1 diabetes there is a predominance of organ systems which 
are frequently affected by congenital anomalies. In this second study we aimed to investigate 
1.) the types of malformations in infants of mothers with GDM or type 2 diabetes and 2.) 
whether the types of anomalies occurring are related to the level of maternal hyperglycemia at 
entry to care. We hypothesize that some organ systems are more susceptible to hyperglycemia 
than others . Study subjects were again retrieved from our database of diabetic women 
attending the Diabetes Clinic of the Los Angeles County women’s hospital. Diagnosed major 
congenital malformations were categorized by the number and type of affected organ systems.  
In a total of 3764 women with GDM and 416 women with known type 2 diabetes 
mellitus. Maternal historical (age, prepregnancy BMI, prior pregnancy with macrosomia, 
stillbirth or anomalies) and clinical parameter (gestational age at first prenatal visit, first 
trimester exposure to sulfonylurea agents) and value of the initial fasting glucose and HbA1c 
were investigated regarding their relation to anomalies. 143 infants (3.4%) with major 
anomalies were identified, with a prevalence of 2.9% in GDM and 8.9% in type 2 diabetes. 
The most frequently affected organ systems were cardiac (37.6%), musculo-skeletal (16%) 
and central nervous system (9.8%).  
In 16% of the infants multiple organ systems were affected. There was no 
predominance seen of any organ system affected with increasing fasting glucose values 
(figure 4). But major anomalies involving multiple organ systems were associated with 
significantly higher glucose levels (166 ± 64 mg/dl) than malformations which were limited to 
one affected organ system (141 ± 55 mg/dl, p=0.006.) 
 
2.1.2 Discussion  
In this first large-scale study in women with GDM, we could confirm the tight 
relationship between maternal glycemia and the rate of congenital anomalies that had been  
 




















demonstrated in women with preexisting type 1 diabetes. Additionally, we saw the same 
predominance of anomalies affecting the heart, skeleton and central nervous system in a  
mixed population of women with GDM and known type 2 diabetes as reported from 
pregnancies with type 1 diabetes.  
The overall rate of major anomalies was slightly higher than in non-diabetic women of 
our population. Our women with GDM had an unusual wide range of  the degree of glucose 
intolerance  partly due to the high level of insulin resistance in the Mexican-American 
population in Los Angeles. 34 There is a great chance that women with fasting glucose values 
above our second identified threshold for an increased risk for anomalies (260 mg/dl) had 
undiagnosed type 2 diabetes before pregnancy. But already glucose levels below the level 
required for the diagnosis of diabetes outside pregnancy  at the time of study (fasting glucose 
140 mg/dl) were related with in increased rate for anomalies. 35 A second analysis in a 
subgroup of women with normal postpartum oGTT and therefor little chance of having 
preexisting diabetes confirmed that women who develop severe glucose intolerance first in 
pregnancy are also at risk for an infant with congenital anomalies. We have no information 
about the glucose values in early pregnancy since in general screening for GDM is 
Figure 4:  
Distribution of affected organ systems in infants with major anomalies according to the
fasting glucose value at entry to care 
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recommended not before 24-28 weeks of gestation. Thus, we could only speculated about the 
degree of hyperglycemia during embryogenesis which is required to cause anomalies. 
Interestingly our identified threshold of a fasting glucose value >120 mg/dl was identical with 
the threshold which was reported for 1st trimester glucose measurement in women with type 1 
diabetes. 31 Regardless the final classification of diabetes after pregnancy, our data provide a 
useful tool to counsel women with hyperglycemia diagnosed first in pregnancy about their 
risk for major anomalies based on their fasting glucose levels at time of diagnosis. Ultrasound 
examination on a high level of expertise should de offered to women with fasting glucose > 
120 mg/dl with special attention to the most frequently affected organ systems. Additionally, 
the high chance for anomalies involving multiple organ systems have to be considered since 
increasing glucose levels had been associated with a higher number of affected organ systems 
in the infants of our population. Further prospective studies are needed to develop strategies 
to identify preconceptionally women without overt diabetes but glucose intolerance sufficient 
to cause congenital anomalies. A minority of the women would have qualified for routine 
diabetes testing which is limited to women with age > 45 or other risk factors like prior GDM. 
36 But even with routine testing the women who appeared to be at risk would not have been 
detected considering the existing diagnostic criteria for diabetes outside pregnancy at the time 
of the study. The rate of major anomalies was more than double in women with fasting 
glucose > 120 mg/dl, a level which was classified as normal by the recommendations of the 
American Diabetes Association from 1996. 36 Meanwhile the diagnostic criteria for diabetes 
outside pregnancy had been modified and a repeat fasting glucose measurement of 125 mg/dl 
in venous plasma and 110 mg/dl in capillary blood qualifies for the diagnosis of diabetes. 37 
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2.2 The influence of maternal glycemic values on fetal growth and neonatal 
morbidity 
2.2.1  Studies in pregnancies with borderline glucose intolerance  
2.2.1.1 Introduction and summary  
The diagnosis of GDM is based on the glucose values obtained by an oral glucose 
tolerance test. There is an ungoing discussion for three decade about the thresholds for 
defining maternal glucose intolerance in pregnancy which resulted in a great variation of 
glucose values used for the definition of GDM  (table 2).  
 


















Load (g) 100 100 100 75 100 75 75 
Method  SM-Nd GO/HKe GO/HK GO/HK GO/HK GO/HK GO/HK 



















1H 165 190 180  180 165 180 180 
2H 145 165 155 140 155 145 155 155 
 
aNational Diabetes Data Group    bAmerican Diabetes Association 
cGerman Diabetes Association    dSomogy-Nelson 
eHexokinase/Glukoseoxigenase,    fWhole venous blood  
gVenous plasma        hCapillary blood 
 
All used definitions were derived from the original criteria from O’ Sullivan and Mahan from 
1964. 21 But these were based on the subsequent maternal risk for diabetes and did not 
investigate the risk for fetal or neonatal morbidity. Furthermore there is more and more 
evidence that the relationship between maternal glycemia during pregnancy and neonatal 
morbidity behaves more like a continuum, with no precise threshold to discriminate between 
high and low risk fetus. 38 39 For termination of thresholds for increased morbidity an 
untreated population of women with glucose intolerance in pregnancy would be needed. Since 
it is unethical to withhold a therapy that had been shown to reduce morbidity, the studies 
addressing this issue were limited to women with glucose intolerance below the existing 
2. Own contributions  16 
 
thresholds for gestational diabetes. They investigated the outcome either in women with 
positive glucose challange test but negative oGTT or in women with only one pathologic 
value in the oGTT. 
 
•  Fetal hyperinsulinism, neonatal obesity and placenta immaturity 
The aim of the present study was to determine the impact of borderline glucose 
intolerance on diabetic fetopathy indicated by neonatal obesity, fetal hyperinsulinism and 
placenta immaturity. Our study was performed between 1992 and 1993 at the Department for 
Obstetrics at the Vivantes Medical Center Neukoelln in Berlin. We involved 325 women with 
risk factors for GDM who were tested for glucose intolerance by a 75 g oGTT. The 
O’Sullivan criteria were applied for diagnosis of GDM. Diabetes care consisting of diet 
education and frequent glucose profiles was limited to women with GDM, defined as usual by 
two pathologic values in the oGTT.  The study population was divided into women with 
normal oGTT, women with one abnormal value (IGT= impaired glucose tolerance) and 
women with GDM and neonatal outcome was compared between the groups. Neonatal 
parameters tested were as followed: birth weight, large-for.gestational-age birth weight 
(LGA), skinfolds at three sites of the newborn (figure 5), amniotic fluid insulin at time of 
delivery, cord blood glucose and insulin, neonatal glucose and villous maturation of the 
placenta. Neonatal obesity was defined according percentile rankings obtained by skinfold 
measurements that had been previously performed in 250 consecutively born infants.  
 
Figure 5:   
Skinfold measurement at the triceps in a newborn 
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Women with one abnormal value had significantly higher rates of LGA infants and 
infants with central obesity, of hyperinsulinism and neonatal hyperglycemia compared to 
women with normal oGTT with a rate similar to women with GDM. Central obesity and 
hyperinsulinism with consecutive neonatal hypoglycemia was even more frequent than in 
pregnancies with GDM. Severe placental immaturity was seen most frequently in GDM 
pregnancies but again the rate in IGT was significantly higher compared to normal 
pregnancies. 
 
•  Neonatal Hypoglycemia in LGA newborns 
Neonatal glucose testing is routine part of neonatal care in infants of mothers with 
known diabetes.  Additionally, neonatal glucose testing is recommended in all LGA infants 
(birth weight> 90th percentile) independently of the diabetic status of the mother. Excessive 
growth is the major clinical sign of fetal hyperinsulinism due to maternal hyperglycemia in 
pregnancy. Macrosomic newborns are at increased risk for neonatal hypoglycemia when after 
delivery the insulin secretion has to be adapted to the sudden drop in glucose supply.  
Universal testing in all LGA newborns implicates unnecessary diagnostic in infants at low or 
no risk for hypoglycemia since only a minority of macrosomia is caused by diabetes. Therefor 
we investigated the rate of hypoglycemia in LGA newborns of non-diabetic mothers and 
whether maternal or neonatal risk factors for hypoglycemia could be identified. In 887 LGA 
infants, we observed hypoglycemia within the first day of life in 16% of the infants with a 
steep decrease of the incidence after the first two hours. 
There was no clinical useful predictor for hypoglycemia unless glucose values of an oGTT in 
pregnancy were available. In the subgroup of infants of mothers with oGTT the 1 hour-
glucose value was an excellent discriminator between infants at low, intermediate or high risk 
for hypoglycemia. Three cutoff points with stepwise increase in the rate of hypoglycemia 
were identified. The rate of hypoglycemia was 2.5% for glucose values ≤ 120 mg/dl, 
increased to 9.3% for values of ≥ 120 and ≤ 179 mg/dl and further to 22% for ≥ 180 and ≥ 
239 mg/dl.  
 
2.2.1.2. Discussion 
Several groups have been shown that women with glucose intolerance below the 
existing thresholds for gestational diabetes have a higher rate of macrosomia, cesarean 
delivery and preeclampsia. 38-42 The best evidence comes from the Toronto Tri Hospital 
study, a prospective study that involved 3600 women with normal oGTT,  patients and care 
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givers were blinded to the glucose values. They could demonstrate a graded increase in 
adverse maternal-fetal outcome with increasing maternal carbohydrate intolerance. 38 In 
addition to other studies which were limited to clinical complications known to be increased 
in diabetes, we could confirmed the influence of borderline glucose intolerance on very 
specific parameters for diabetic fetopathy. Beside macrosomia and hypoglycemia also 
hyperinsulinism, trunk obesity and placenta immaturity were significantly more frequent in 
untreated women with IGT than in normal women. Our second work related to this topic 
concentrated on macrosomic infants of non-diabetic mothers. We could show that the risk of 
neonatal hypoglycemia in these infants is tightly related to the 1-hour oGTT value of the 
mother. Interestingly, the identified threshold corresponds to the threshold for an abnormal 1-
hour value according to the Carpenter and Coustan criteria for GDM. 20 Thus, all mothers of 
the infants at greatest risk for hypoglycemia had IGT that was not treated because the oGTT 
did not fulfill the criteria for GDM. Secondly, our data support the clinical importance of a 
general screening for GDM since without available oGTT values a risk assessment for 
hypoglycemia in LGA newborns seems not be possible. 
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2.2.2 The impact of maternal obesity 
2.2.2.1 Introduction and summary  
The hypothesis of Pedersen proposed that glucose from the maternal circulation is a 
major regulator for fetal growth. 14 A large body of clinical and experimental studies 
supported that maternal hyperglycemia enhances fetal growth by an excessive glucose supply 
to the fetus at a time when the fetal pancreas is able to respond by increasing its production of 
insulin. 43-45 Although the stimulation of insulin secretion starts with 11-15 weeks of 
gestation 46 , accelerated growth due to maternal diabetes occurs at around 28 weeks, 
presumable because of the fetal capacity to store triglycerides at that time. 47 Thus, it is 
obvious that maternal hypergylcemia is a risk factor for macrosomia, however the regulation 
of fetal growth is far more complex and is influenced by many factors. The clinical 
experience indicates that despite of tight glucose control neonatal macrosomia occurs. On the 
other side, normosomic infants are born to mothers with hyperglycemia. 
 
• The correlation of maternal obesity and high rates of fetal macrosomia 
Existing studies are limited to the investigation of the influence of maternal glycemia 
and LGA at time of birth. Our study aimed to examine the correlation of maternal glucose 
values and fetal growth at different gestational weeks of pregnancies in normal and 
overweight women with GDM. In 406 women with GDM or IGT a total of 919 serial 
ultrasound examinations was performed. A fetal abdominal circumference > 90th percentile 
according to gestational age 48 was defined as fetal macrosomia. Glucose values at diagnosis - 
oGTT , entry glucose profile and HbA1c – and the glucose values of the profiles  performed 
at 5 different categories of gestational weeks were compared between pregnancies with and 
without fetal macrosomia diagnosed at correspondent gestational ages. Each analysis was 
adjusted for maternal obesity, defined as body mass index (BMI) ≥ 30 kg/m2. 49 There was no 
difference in glucose values either at entry or during pregnancy between pregnancies with or 
without fetal macrosomia either in lean nor in obese women. In contrast, the fetal macrosomia 
rate was significantly higher in obese compared to lean women at each category of gestational 
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• Determinants for in utero macrosomia at different gestational ages 
Our first work revealed the strong influence of maternal obesity on fetal growth. In a 
second step, we investigated the influence of other maternal parameters. We use the above 
described population to determine independent predictors for fetal macrosomia at different 
periods of pregnancies and at birth. We included maternal historical (prior pregnancy with 
LGA or GDM, prepregnancy BMI and parity) and glycemic parameters at entry (oGTT, 
HbA1c and mean fasting and postprandial glucose values of the daily profile) and the glucose 
values of the profiles at the different periods of pregnancy. We found different parameters 
univariately associated with accelerated growth at different times of pregnancy: LGA in a 
previous pregnancy, parity, prepregnancy obesity, fasting of the oGTT or fasting glucose at 










                              





Timeline of independent predictors for an AC≥90th percentile at entry, in different gestational 
age categories and for large-for-gestational age birth weight in pregnancies with GDM and 
IGT. (Odds Ratio and 95%CI given). Obesity was defined as BMI ≥ 30 kg/m2. OR per 5 
mg/dl increase of fasting glucose 
 
Gestational age (weeks)
     1.04  
(1.01-1.08)* 
Fasting Glucose 
at 32-35 weeks 
Prepregnancy 
Obesity 
Prior history of  
Macrosomia 





     3.6  
(1.8-7.3) 
    9.8  
(3.0-32)  
    4.2  
(1.5-11)  
    2.7  
(1.3-5.6)  
Entry 24 28 36 32 Birth 
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2.2.2.2. Discussion 
The complexity of fetal growth occurs at several levels determined by the mother, the 
placenta and the fetus. Both of our presented studies revealed the strong influence of maternal 
obesity on the risk for accelerated growth. At no time in pregnancy, a higher rate of fetal 
macrosomia was associated with higher maternal glucose values but with obesity. Obesity is 
often associated with elevated lipids and proteins and peripheral hyperinsulinism which had 
been shown to be related to the risk for macrosomia. 50-52 Lipids and amino acid levels are 
influenced by the carbohydrate metabolism but there is no linear correlation between the 
elevation of glucose and non-glucose nutrients. Thus, the effect of hyperlipidemia and 
hyperacidemia on fetal growth cannot be eliminated solely by glucose control.  When we 
looked for other maternal predictors in the second analysis, we found independent predictors 
that represent the three major determinants of fetal growth. A history of a prior LGA infant 
representing the genetic influence, maternal obesity reflecting genetic and non-glucose fuels 
and the fasting hyperglycemia indicating an increased glucose supply to the fetus. In the early 
pregnancy the influence of genetic factors predominates; about 15% of the variation in birth 
weight is due to genetic predisposition. 53 It could be shown that an early symmetric 
accelerated growth is not associated with fetal hyperinsulinism. 54 In the early third trimester 
maternal obesity became a strong predictor coincident with the time of fetal adipocyte 
proliferation and lipid storage. Maternal glycemia appears to have the strongest influence in 
the late trimester, the time when accelerated growth in diabetic pregnancies was described 55, 
56. Maternal hyperglycemia leads via fetal hyperinsulinism to an increase of the insulin 
sensitive tissue, like the adipose tissue.  
In summary, our GDM management that was focused on tight glucose control could 
not lower the macrosomia rate in obese women. Considering the strong influence of non-
glucose related parameters, a modified approach in obese women might be more effective to 
lower the high rate of LGA infants in these women. 
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2.3. The importance of the fetal abdominal circumference in pregnancies with 
diabetes 
2.3.1. Introduction and summary  
As demonstrated above, the reliability of maternal glycemic values to predict diabetic 
morbidity in the newborn is limited. Normalization of maternal hyperglycemia could lower 
the rate of adverse outcome in pregnancies with GDM but the rate of macrosomia and 
neonatal morbidity is still elevated compared to the normal obstetrical population. 1 In studies 
with very strict control the macrosomia rate had been lowered to 10% but this management 
required intensive insulin therapy in 66-100% of the women. 57-59 Furthermore, in gestational 
diabetes aggressive lowering of the maternal glucose levels may lead to an increased rate of 
intrauterine growth retardation and an adverse perinatal outcome for small-for-gestational-age 
newborns. Attainment of strict control in all women with GDM might result in unnecessary 
treatment in low-risk pregnancies and absorption of limited resources needed for intensive 
therapy in high-risk pregnancies.  Therefor some researchers were looking for other predictors 
besides  maternal glycemia to identify pregnancies at high risk for morbidity. One approach is 
based on fetal growth 60-62 and limits intensive insulin therapy to pregnancies with accelerated 
growth of the fetal abdominal circumference (AC). Diabetes associated macrosomia is 
characterized by an asymmetric growth of the fetal abdomen versus head and long bones due 
to the stimulation of the insulin sensitive fat tissue by fetal hyperinsulinism (fig.1 ). 63, 64 In 
diabetic pregnancies, the fetal AC ( fig. 7) measured in the early third trimester revealed to be 
a good predictor for a LGA newborn. 47, 55, 56  
 
Figure 7 
Measurement of the fetal abdominal circumference 
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The second approach uses amniotic fluid insulin to diagnose fetal hyperinsulinism. 65-
68 The level of fetal insulin is supposed to correspond to the level of insulin in the amniotic 
fluid secondary to the urinary excretion. When insulin levels are elevated, insulin therapy is 
either initiated or intensified. Although this approach offers a direct estimation of the fetal 
reaction on maternal glycemia, it is not widely accepted because it requires an amniocentesis 
as an invasive procedure to obtain amniotic fluid. 
 
• Fetal abdominal circumference as predictor for neonatal macrosomia 
Existing data demonstrate the tight relation of the fetal AC in the third trimester with 
the LGA status at birth but there is a paucity of data investigating the predictive power of the 
fetal AC compared to maternal parameters known to influence fetal growth. Therefor we 
determined independent predictors for LGA and their predictive power. Secondly, we aimed 
to create a score of the discriminatory parameters and quantitated the  predictive power by 
receiver operator characteristics (ROC) curves analysis. In 728 women treated for GDM four 
independent predictors could be identified: a history of GDM, prior delivery of an infant > 
4000 g birth weight, prepregnancy BMI ≥ 30 kg/m2 and fetal AC ≥ 90th percentile at entry 
with the fetal AC being the strongest predictor (OR 3.9) (unpublished data 5.3). None of the 
glycemic parameters revealed to be predictive. The area under ROC curve of a score based on 
the three historical risk factors was 0.66, which could be increased to 0.71 by inclusion of 
fetal AC at entry to diabetes therapy  (p>0.05). The negative predictive value (NPV) for 
women with no risk factor was 0.90 and improved to 0.93 when the fetal AC was considered 
as well. Subsequent ultrasound examinations did not improve predictive power of the score. 
 
• Correlation of amniotic fluid insulin levels and fetal abdominal circumference at time of 
amniocentesis 
The fetal AC measurement is an indirect approach to assess fetal morbidity in 
pregnancies with diabetes based on a clinical manifestation of fetal hyperinsulinism. But since 
fetal growth is influenced by many other factors beside the fetal insulin levels there is still a 
concern of over- or under-treatment when insulin therapy is administered solely depending on 
the fetal AC. Thus, we investigated the correlation between amniotic fluid insulin (AF 
insulin) and fetal AC percentiles at time of amniocentesis performed in the third trimester in 
121 diabetic women.  In a second step, we aimed to find a threshold for fetal AC 
measurements that identifies low vs high risk levels of AF insulin without performing an 
amniocentesis. We could show that AF insulin levels were significantly correlated with the 
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AC percentiles (r=0.3, p=0.0005) by linear regression. Division of the cohort according to AC 
percentiles revealed a significant stepwise increase in AF insulin ≥ 7 µU/ml at the 80th 
percentile of the AC. An amniotic fluid insulin >7 µU/ml was previously defined as 90th 
percentile of a normal obstetrical population by our group. 69 But the negative predictive 
value (NPV) was low (77.6 %) and the ROC curve confirmed that there was no good 
threshold of the fetal AC to identify an AF insulin ≥7 µU/ml (fig 8). In contrast an AC 
threshold ≥ 75th percentile could reliably identify fetal hyperinsulinism with an AF insulin 
>16 µU/ml. All 10 cases of AF insulin >16 µU/ml were identified with a NPV of 100%  
(74/74).  
 
Figure 8:  ROC curves for the fetal abdominal circumference to identify amniotic fluid insulin 
≥ 7 µU/ml and ≥ 16 ≥ 7 µU/ml 
 
2.3.2. Discussion  
Both our studies support the importance of the fetal AC in the management of 
pregnancies with diabetes. The percentiles of the fetal AC corresponded to the level of the 
fetal insulin indirectely determined by the AF insulin. The fetal AC ≥ 90th percentile was the 
strongest predictor for an LGA infant within a wide selection of tested parameters. In contrast, 
as we expected from our previous studies, the maternal glycemic values in this treated 
population were not predictive. We can only speculate if maternal glycemia would be more 
discriminative in an untreated population with a wider range of glycemic values.  
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Surprisingly, the predictive power of a score created from historical data was only slightly 
improved by inclusion of the fetal AC. Easy obtainable historical data by itself seem to 
provide enough information for clinicians to antenatally estimate the risk for an LGA 
newborn. All predictors in a single or combined fashion are superior in identifying an infant at 
low risk for excessive growth (NPV) while the sensitivity and specificity did not exceed 77% 
or 53%, respectively. Similar, the identified threshold fetal AC for an increased risk for severe 
fetal hyperinsulinism was highly reliable in excluding hyperinsulinism but weak in predicting 
elevated insulin levels > 16 µU/ml. For moderately elevated insulin levels the fetal AC offers 
no reliable tool for risk assessment. Almost 50% of the cases would have been missed by the 
identified AC threshold for AF insulin > 7 µU/ml. Kainer et al, the only group so far that 
investigated the relation of amniotic fluid insulin and the fetal AC also found the AC 
measurement to be useful only in identifying high levels of insulin. 70 Our finding 
corresponds to the data of Weiss et al who had demonstrated that neonatal morbidity was 
mostly limited to AF insulin levels which were increased 2 - 3 fold above normal. 66  There is 
evidence that excessive birth weight is limited to markedly AF insulin levels about ≥ 20 
µU/ml 66, 71. Similarly, long term effects of fetal hyperinsulinism like an increased rate of 
childhood obesity also appear to be restricted to the levels of AF insulin ≥ 20 µU/m. 72 These 
insulin levels correspond closely to the insulin level of ≥ 16 µU/ml that according to our data 
can be identified by an AC ≥ 75th percentile. Interestingly, the AC threshold of the 75th 
percentile found by our study to identify severe hyperinsulinism was identical to the AC 
threshold which has been recommended for initiating insulin therapy in GDM. 60-62  
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2.4. Intervention studies – management of GDM based on fetal growth 
 
2.4.1 Introduction and summary  
Fetal growth in pregnancies complicated by diabetes is related to maternal glycemia 
but it is controversial to what extend hyperglycemia determines morbidity. 1 In agreement 
with other groups, we could show that the relation of neonatal morbidity and maternal glucose 
values seems to behave in a continuous fashion. 38, 42, 73-76   Thus, the glucose targets that we 
aim to achieve during pregnancies are arbitrary and consensus based. Recently it had been 
shown that the 97th percentile of the 1-hour postprandial glucose value of women with normal 
glucose tolerance is far below the recommended cutoff for insulin therapy of 140 mg/dl. 77 
The best evidence that the same maternal glucose values may result in different outcome 
comes from observations in twins. 78 Applying the strategy of tight glucose control on all 
women misses the change to target intervention on pregnancies with high risk for morbidity. 
In a pilot study limited to women with normoglycemia it was demonstrated that a single 
measurement at entry to therapy could identify a fetus at risk for macrosomia. Intensive 
insulin therapy could lower the macrosomia rate by 3 fold in this high risk population 
compared to those who were treated with diet only. The overall macrosomia rate of the study 
population was reduced without applying insulin to the majority of the women. Our 
subsequent studies which will be presented in the following aimed (1) to extend this approach 
to women with hyperglycemia and (2) to proof the applicability of this strategy in a 
population with a different ethnic background and without prior stratification according to the 
maternal glycemia status. 
 
• Fetal growth based approach applied in Latino women limited to women with maternal 
hyperglycemia  
 Eighty-nine women with GDM and venous fasting glucose levels > 105  < 200 mg/dl 
after a 1 week trial of diet were randomized to a standard and an experimental group. The 
standard group was treated with insulin due to maternal hyperglycemia. In the experimental 
group insulin therapy was limited to pregnancies with a fetal AC > 70th percentile at entry or 
in one of the subsequent monthly ultrasound examinations. Additionally, insulin was applied 
when maternal glucose exceeded fasting > 120 mg or postprandial 200 mg/dl. There was no 
difference in maternal characteristics at entry between the two study groups. According to the 
protocol, the glucose values during pregnancy were lower in the standard group compared to 
the experimental group. In the experimental group (n=48), insulin therapy was applied in 27 
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(56%) women because of fetal AC > 70th percentile, in 3 women because of fasting glucose > 
120 mg/dl or non-compliance and in 18 (=38%) insulin could be withhold. The neonatal 
outcome did not differ between the groups with overall low rates of LGA newborns (6.3 vs 
8.3 % for standard versus experimental group). Delivery by Cesarean section was performed 
more frequently in the experimental group but this could not be explained by complications 
related to diabetes. Despite intensive insulin therapy the LGA rate in women with fetal AC > 
70th percentile at entry was higher than in women with normal fetal growth. 
 
• Evaluation of the fetal growth based approach in a Caucasian population without respect to 
maternal glycemia status 
 In this study women with diagnosis of GDM according O’Sullivan criteria were 
enrolled who attended the Diabetic Prenatal Care Clinic either of the Charité or of the 
Vivantes Medical Center in Berlin. Both institutions take care of a multiethnic population 
with a rate of approximately 40% women from Turkey, Arabian countries or East Europe. 
Women from Latin-America are rare. The women were randomized to a standard (n=100) and 
an ultrasound group (US-group, n=99) when fasting glucose < 120 mg/dl and postprandial 
values < 200 mg/dl in the glycemic profiles after one week of diet. In the standard group, 
women stayed on diet unless fasting glucose > 90 mg/dl and/or postprandial glucose >120 
mg/dl. The US-group was started on insulin if fetal AC exceeded the 75th percentile at entry 
or at any examination thereafter corresponding to a 4 week examination schedule at 20, 24, 
28, 32 weeks of gestation. Additional, insulin was recommended in case of severe maternal 
hyperglycemia defined as fasting glucose > 120 mg/dl or postprandial > 200 mg/dl. The two 
groups were similar regarding historical data, glycemic data and the rate of fetal AC at entry. 
In the US-group insulin was given exclusively based on AC > 75th percentile. Neonatal 
outcome was not significantly different in both groups. When we analyzed a subgroup of 
women with GDM according to Carpenter and Coustan criteria (n=161) the results were 
identical with the exception of a higher rate of insulin use in the standard group. In a 
secondary analysis in women with euglycemia and AC >75th percentile (n=34) the rate of 
LGA, C-section and neonatal hypoglycemia was lower in the insulin treated US-group 
compared to corresponding women in the standard-group. In those pregnancies with maternal 
hyperglycemia but AC< 75th percentile (n=35) there was no adverse outcome in the US-group 
although insulin was withheld.  
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2.4.2 Discussion 
Both our studies demonstrated that a management based on relaxed glycemic criteria 
combined with fetal AC measurements is a safe approach for mother and child independent 
on the ethnic background of the study population. The measurement of the fetal AC with 
ultrasound reliably identified fetuses at low risk for accelerated growth. This supports the 
prior work of Bochner, Landon and Ogata. 47, 55, 56 In GDM managed by a fetal-growth based 
approach the neonatal outcome was similar to pregnancies guided solely by maternal 
glycemia even in selected women with hyperglycemia from a population of Mexican-
Americans that is known to have a high rate of severe glucose intolerance. 34 Insulin therapy 
could be avoided in 38 % of these women and in 43% of Caucasian women with 
hyperglycemia investigated in Berlin. The “Berlin study” combined the two pilot studies from 
Los Angeles and included both women with normoglycemia and hyperglycemia. The overall 
rate of insulin use was slightly higher in the US-group compared to the standard approach. 
This reflectes the mild degree of glucose intolerance when diagnosis of GDM is based on the 
low diagnostic criteria for GDM of O’Sullivan. 21 When we excluded women who did not 
fulfill the Carpenter and Coustan criteria that require higher post challenge glucose values, the 
insulin use in both study arms was similar. When we looked at the women who were treated 
differently in the US-group compared to the standard group we realized a better outcome in 
the US-group: a tendency toward a lower SGA rate in women with hyperglycemia but normal 
fetal growth and a lower LGA rate in women with euglycemia but accelerated growth. The 
last finding confirmed the study of Buchanan. 60 Interestingly, in both studies the LGA rate 
was unexpectedly low in the standard group. It can be only speculated about the influence of 
increased attention and motivation under the conditions of a clinical trial and the frequent 
demonstration of fetal growth by serial ultrasound examinations.  
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Condension 
Maternal historical parameters and the fetal abdominal circumference predict an LGA infant 




Objective:  The aim of treatment of women with gestational diabetes (GDM) includes 
prevention of the development of a large-for-gestational-age infant (LGA). To reserve 
intensified interventions for women at increased risk, we investigated potential LGA 
predictors and asked if inclusion of fetal ultrasound could enhance predictive power. 
Research Design: In 728 women treated for GDM, maternal history variables, maternal 
glycemic values, and fetal abdominal circumference (AC) at entry and thereafter were 
compared between LGA and non-LGA infant women. Parameters identified by univariate 
analysis were investigated for their ability to predict LGA individually or collectively. 
Results: A history of GDM (OR 1.9), prior delivery of an infant >4000 g birth weight (OR 
2.2), prepregnancy BMI ≥30 kg/m2 (OR 2.4), and fetal AC ≥90th percentile at entry (OR 3.9) 
but not glycemic values were independent predictors of LGA. The area under a receiver 
operator characteristics curve of a score based on historical risk factors was 0.66. The area  
increased to 0.71 or 0.72 after inclusion of one or two fetal AC measurements, respectively. 
The negative predictive value for women with no risk factor excluding or including 
ultrasound at entry (n=437 and 356) was 0.90 and 0.93, respectively (p > 0.05). Subsequent 
ultrasound examinations did not improve predictive power. 
Conclusions: In women treated for GDM, maternal history and sonographically-determined 
measures of fetal AC independently predict delivery of an LGA infant while glycemic values 
do not. However, the predictive value of these parameters is limited and is only slightly 
improved by the inclusion of ultrasound.  
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Introduction 
 Excessive growth due to fetal hyperinsulinism is a major clinical problem in 
pregnancies complicated by gestational diabetes (GDM). Presumably, infants born large-for-
gestational-age (LGA) to mothers with GDM have been exposed to hyperglycemia in utero 
for prolonged periods of time and therefore are more prone to its long-term metabolic 
sequelae. In addition, LGA infants are at increased risk for obstetrical complications, and the 
rate of birth injuries of LGA infants born to GDM mothers even exceeds that of LGA infants 
born to non-GDM mothers. 1  
To prevent the development of a LGA infant, interventions during pregnancy are 
focussed on the maintenance of maternal glucose values within a strict range supposed to 
reduce the risk for neonatal macrosomia and other morbidities. Despite apparently successful 
efforts toward maternal glycemic control the macrosomia rate in pregnancies complicated by 
gestational diabetes (GDM) is often reported to be higher than in a normal obstetrical 
population. 2-4 Antenatal risk assessment for LGA might improve the management of women 
who have GDM. In the present study, we evaluated the predictive ability of antenatal risk 
factors for the development of a large-for-gestational-age (LGA) infant and specifically 
assessed the contribution of individual or serial measurements of the fetal abdominal 
circumference (AC) by ultrasound. A score was created of the discriminatory variables, and 
its predictive power quantitated by receiver operator characteristics (ROC) curve analysis.  
 
Research  Design and Methods 
Study population 
Subjects were retrospectively selected from the population of women with glucose 
intolerance who attended the Diabetes Clinic of the Department of Obstetrics of an urban 
community hospital between 1994 and 2000 and had been entered into an ongoing database. 
Study inclusion criteria were: 1.) documented glucose intolerance first diagnosed in 
pregnancy ; 2.) accurate gestational age, confirmed by an ultrasound examination before 20 
weeks of gestation; 3.) singleton pregnancy; 4.) at least one complete fetal biometry 
determined by ultrasound at entry to diabetic  therapy; 5.) absence of identified fetal 
anomalies; 6.) documented data regarding maternal obstetrical history and anthropometry and 
7.) documented delivery data.  
Reflecting obstetrical standards in Germany, testing for GDM in our study subjects was 
performed selectively in women with risk factors. In women with historical risk factors 
testing was preformed in the first trimester otherwise whenever risk factors first occurred (e.g. 
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glucosuria) or were diagnosed (e.g. fetal macrosomia). The diagnosis of GDM was 
established by a 75g oral glucose tolerance test (oGTT) with determination of capillary blood 
glucose levels by glucose oxidase (Beckman Glucose Analyzer, Brea, CA). Diagnostic 
criteria for GDM valid in Germany at the time of study were: fasting >90 mg/dL (5.0 
mmol/l); 1 hour >165 mg/dL (9.1 mmol/l), 2 hour >145 mg/dL (8.0 mmol/l) (adopted from 
O’Sullivan 5). Diagnosis of GDM required at least two abnormal values, and of impaired 
glucose tolerance (IGT) one abnormal value.  
Women with GDM and IGT were educated regarding an individualized diabetic diet 
based on prepregnancy weight  (30 kcal/kg/d) with caloric restriction for obese women  (25 
kcal/kg/d). All women were instructed to self-monitor blood glucose (SMBG) by performing 
a daily glucose profile (3 preprandial and 3 1-h-postprandial measurements) twice a week 
using a reflectance meter with electronic memory (Advantage Glucose meter, Roche 
Diagnostics, Germany). Accuracy of the glucose meters was tested biweekly by comparison 
with a laboratory glucose measurement  (glucose oxidase). Insulin therapy was recommended 
when the mean of all glucose values of a profile exceeded 100 mg/dL (5.5 mmol/l) after a 
two-week trial of diet. Insulin dose was adjusted to achieve fasting glucose values ≤90 mg/dL 
(5.0 mmol/l) and 2 hour postprandial values ≤120 mg/dL (6.6 mmol/l). Women treated with 
insulin therapy were asked to perform glucose profiles every day.  
An initial ultrasound examination with complete fetal biometry was scheduled at the 
entry visit and monthly in conjunction with Diabetes Clinic visits. The fetal abdominal 
circumference (AC) was measured in the standard cross-section view of the abdomen. 6 
 
Potential risk factors and outcome data 
Maternal parameters assessed included age, parity, history of prior macrosomia (birth 
weight ≥90th percentile for gestational age in at least one previous pregnancy 7) or GDM, 
prepregnancy body mass index (BMI) and weight gain during current pregnancy. Glycemic 
parameters included gestational age (GA) at time of diagnosis, glycosylated hemoglobin 
levels (HbA1c) at diagnosis, glucose levels of the diagnostic oGTT and from of the daily 
glucose profiles during pregnancy and insulin use.  
The only fetal measurement utilized was the AC percentile for gestational age. All 
ultrasound measurements performed during the study were divided into 5 categories 
according to gestational age at time of examination, i.e. < 24, 24/0 –27/6, 28/0-31/6, 32/0-
35/6, and 36/0 to 40/0 weeks/days. For purposes of data analysis AC measurements were 
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classified as either ≥ or < 90th percentile for gestational age according to standards published 
by Hadlock, et al. 6 
Newborn parameters included birth weight and length and classification of the infants as 
large-for-gestational-age (LGA) or non-LGA. LGA was defined according the 90th percentile 
for gestational age using current German growth curves. 7 
 
Statistical analysis 
Differences between pregnancies resulting in LGA and non-LGA neonates at birth were 
tested for statistical significance by the Mann Whitney U test (continuous variables) or by χ2 
analysis (categorical variables). Data are presented as mean ± SD. 
A multivariate logistic regression analysis was performed to determine independent 
predictors of LGA neonates with their associated odds ratios. The sensitivity, specificity, 
positive and negative predictive value (PPV/NPV) to predict LGA were calculated for each 
predictor and for scores which combined all identified predictors. The scores were created 
based on the number of absent or present of identified risk factors, either with or without 
inclusion of a fetal AC ≥ 90th percentile as additional risk factor diagnosed exclusively at the 
first or at the first or second ultrasound. The predictive values were calculated for different 
cutoff points; absence of any versus presence of at least 1 risk factor, presence of 0-1 versus at 
least 2 risk factors and 0-2 versus at least 3 risk factors. The predictive power of each score 
was described by the area under a ROC curve. 




A total of 1058 women had been entered in the database until December 2000. Of 
these, 54 women were excluded because of preexisting diabetes, and 276 women because of 
missing data, thus leaving 728 women for the final analysis. 552 (75.8 %) of the women were 
diagnosed with GDM, and 176 (24.2%) with IGT. While GDM women had significantly 
higher oGTT values, as compared to IGT women (fasting: 96.7 ± 22.0 vs 81.5 ± 23.9 mg/dL; 
1 hour 204.1 ± 31.1 vs 179.9 ± 35.6 mg/dL; 2 hours 158.8 ± 37.1 vs 120.3 ± 25.3 mg/dL; p< 
0.0001 for all comparisons), higher entry HbA1c levels (6.1 vs 5.4 %, p=0.05), and required 
insulin therapy more often (16.7.2% vs 6.3 %, p = 0.001), 3rd trimester glycemic control after 
initiation of therapy was not different between GDM and IGT women, as measured by fasting 
3. Relevant original publications  36 
 
and postprandial glucose values. Historical parameters did not differ significantly between the 
two groups, as did AC measurements at entry (AC ≥ 90th percentile, 21.7 % vs 24.7%) or 
LGA at birth (16.3 vs 13.6 %). Therefore, women with GDM and IGT were analyzed 
together.  
A total of 1712 ultrasound examinations were available for analysis. Out of 728 
subjects, in 35.1 % one ultrasound examination, in 23.7% two and in 41.2 % three to five 
examinations were performed. The entry ultrasound examinations were distributed almost 
equally between those performed prior to 28 weeks (38.1%), between 28 to 31/6 (29.0%) and 
32/0 to 36/0 weeks /days (34.9). (Only 8 scans at entry were performed beyond 36 weeks of 
gestation) At entry, an AC ≥ 90th percentile was found in 22.4 % (177) of the pregnancies and 
there was at least one event of an AC ≥ 90th percentile throughout pregnancy in 26.5% (193) 
of the infants. 
A total of 114 (of 728, 15.7%) women delivered an LGA infant. Table 1 displays 
maternal characteristics of mothers of LGA compared to those of non-LGA infants. (table). 
There was no difference in gestational age at diagnosis between pregnancies resulting in a 
LGA infant compared to AGA newborns.  The LGA rate was 16.4% when GDM was 
diagnosed < 28 weeks of gestation and 14.9% for ≥ 28 weeks (p= 0.3).  A fetal AC ≥ 90th 
percentile at entry or thereafter was found more frequently among babies destined to be LGA 
(p<0.0001, table 1). LGA infants were delivered significantly earlier than non-LGA newborns 
thus the maternal parameter weight gain was examined for difference between the two groups 
after adjusting for gestational age at delivery.   
The multivariate regression analysis revealed four independent predictors for a LGA 
newborn (table 2). Calculations of the predictive power of the identified predictors are 
displayed in table 2. The NPV value of the fetal AC was slightly improved by a second 
ultrasound while a third measurement did not further increase the predictive power. 
Ultrasound examinations performed at different gestational ages (20/0-23/6, 24/0 –27/6, 28/0-
31/6, 32/0-35/6, or > 36/0 weeks/days) had virtually identical NPV values (88.1% - 91.0%). 
Scores were created combining the three identified historical risk factors, either with or 
without inclusion of one or two fetal AC measurements. For primiparae only the maternal 
BMI and the fetal AC was used as risk factors for the score. The predictive power is displayed 
in table 3. The area under the ROC curve was 0.61 for historical risk factors alone, 0.71 with 
inclusion of one and 0.72 of two ultrasound examinations. The area under the ROC curves of 
the two scores including ultrasound did not differ significantly compared to the score based 
only on historical factors (p = 0.12 and 0.14, respectively). 
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Comment 
In this large-scale retrospective study of pregnant women treated for glucose 
intolerance, we identified and evaluated antenatal risk factors for delivery of an LGA infant 
and specifically assessed the value of repeat fetal AC ultrasound measurements. There are 
three major findings: First, a history of a prior baby weighing ≥ 4000 g, a prior maternal 
history of GDM, a maternal BMI ≥ 30 kg/m2 were predictors of LGA babies. Second, fetal 
AC at entry was the strongest predictor of LGA neonates. However, the addition of the first 
fetal AC measurement to the maternal historical predictors improved the predictive power 
only slightly, and additional ultrasound examinations were of no further value. Third, all 
predictors, individually or collectively, had a limited ability to predict a LGA infant in this 
cohort of women.  
In contrast to others’ works, this study included detailed data documenting maternal 
glycemic values at entry and thereafter, and numerous consecutive ultrasound measurements 
of fetal growth. None of the glycemic parameters either at entry or thereafter was associated 
with LGA at birth. In untreated pregnant women with impaired glucose tolerance glucose 
values have, however, been found to be related to macrosomia. 8 The more stringent criteria 
defining need for treatment in our study and subsequent good glycemic control might explain 
the complete loss of the discriminative power of the glycemic parameters. In addition, factors 
besides maternal concentrations of glucose have been reported to be associated with birth 
weight. 9, 10,11  
The strongest predictor of an LGA neonate was a fetal AC > 90th percentile at entry 
with a 4-fold increase of the risk for LGA. A large amount of data investigated the predictive 
power of ultrasound measurements for macrosomia at birth. 12-18 There is an agreement about 
the unsatisfied accuracy of the estimation of fetal weight obtained by ultrasound at term to 
predict an LGA newborn, especially in diabetic pregnancies or in extremely overweight 
infants. 17  Sonographic weight estimates are derived from cross-sectional data.  Fetuses with 
accelerated growth due to maternal diabetes have been shown to have an increase in adipose 
tissue, which is less dense than fat-free tissue (e.g. muscle and bone).  Thus the application of 
tables derived from an unselected patient population may lead to sonographic overestimation 
of fetal weight 19, 20.   This might explain our finding of a high false positive rate of the AC in 
predicting LGA babies which is consistent with the reports of others 13, 15. However, there is 
evidence that the fetal AC is the best of all fetal measurements to identify macrosomic 
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growth. 12, 13, 15, 18 Recently, our group demonstrated that a fetal AC < 75th percentile reliably 
excluded fetal hyperinsulinism at a level which is known to be associated with morbidity. 21  
Few studies have assessed the utility of serial measurements in predicting birth weight, 
15 but failed to provide information on how much incremental improvement in prediction is 
accrued with each additional examination. According to our data, the predictive power of 
repeat ultrasound examinations does not differ considerably from those of a single 
examination at entry. Surprisingly, the gestational age when the AC was obtained seemed to 
have a limited influence on the NPV. Most of the existing studies performed the AC 
measurement during a defined tight period (30-36 weeks) 14, 15 and did not determine the 
predictive power at different times of pregnancy.  
In summary, there are antenatal maternal and fetal factors in GDM pregnancies which 
are significantly associated with an increased risk for accelerated growth but the delivery of 
an LGA infant in pregnancies complicated by GDM seems not to be predictable. Neither a 
single parameter, nor the combination of multiple maternal risk factors nor the inclusion of 
measurements of the fetal AC showed a satisfying predictive power. Likely due to the low 
incidence of LGA in our cohort, identification of those with a low LGA infant risk was 
possible with reasonable accuracy. The establishment of more specific, and easily 
reproducible sonographic measures of evolving diabetic fetopathy in utero as part of the 
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Maternal characteristics and glycemic values in GDM pregnancies with and without LGA 
newborns(continuous variables expressed as mean ± SD) 
 
         






Maternal history    
Age (years) 30.5 ± 5.4 31.1 ± 5.2 0.2 
Multiparae (%) 54.9 67.0 0.01 
Prepregnancy  BMI (kg/m2) 26.9 ± 6.0 29.9 ± 5.9 0.000 
Prepregnancy  BMI >30 kg/m2   (%) 24.8 42.1 0.000 
Prior GDM (% of multiparas) 19.2 37.7  0.001 
Prior Macrosomia (> 4000 g) (% of 
multiparas) 
14.2 41.8 0.000 
Maternal glycemic values    
     Gestational age at diagnosis 26.5 ± 5.6 26.0 ± 5.9 0.4 
     Oral glucose tolerance test                    
     - fasting (mg/dl) 
 
92.7 ± 24.3 
 
93.9 ± 18.5 
 
0.6 
     - 1-h mg/dl) 198.2 ± 34.3 196.9 ± 43.2 0.7 
     - 2-h (mg/dl) 148.8 ± 38.6 151.5 ± 38.2 0.5 
     IGT  (%) 24.6 20.9 0.6 
Glycemic values at study entry    
     Fasting of the profile 80.6 ± 14.1 83.4 ± 14.1 0.064 
     Postprandials of the profile 112.7 ± 15.3 116.5 ± 14.5 0.3 
      HbA1c (%) 5.7 ± 1.3 5.9 ± 1.2 0.09 
Mean of fasting glucose during pregnancy   
   28-31/6  weeks  81.5 ± 14.7 83.4 ± 15.3 0.4 











 Mean of postprandial glucose during pregnancy   
    28-31/6  weeks 106.3 ± 18.5 107.5 ± 18.6 0.7 
    32-35/6 weeks 105.5 ± 17.3 104.9 ± 17.5 0.8 
Weight gain (kg) 11.8 ± 7.7 12.7 ± 5.9 0.3 
Insulin use (%) 13.3 11.8. 0.2 
Fetal and neonatal parameter    
AC ≥ 90th percentile at entry (%) 17.7 47.8 < 0.0001 
At least 1 AC ≥ 90th percentile (%) 21.4 53.9 0.0000 
GA at delivery (weeks) 39.0 ± 1.7 38.6 ± 1.9 0.04 







Sensitivity , specificity , positive and negative predictive value (PPV, NPV) of the identified 
independent predictors for LGA in pregnancies with GDM  
 OR (95% CI) Sensitivity Specificity PPV NPV 
Prior pregnancy with 
macrosomia 
1.9 (1.07-3.5) 39.5 92.0 28.1 87.3 
Prior pregnancy with GDM 1.9 (1.2-4.2) 31.6 89.4 26.3 86.7 
Maternal BMI ≥ 30 kg/m2 1.9 (1.2-3.) 42.5 75.5 24.2 87.6 
AC ≥ 90th percentile at entry 3.9 (2.4-6.2) 48.7 82.4 33.7 89.6 
At least 1 event of AC ≥ 90th  
in 1st or 2nd US 
3.8 (2.4-6.1) 59.4 78.9 33.5 91.5 
At least 1 event of AC ≥ 90th in  
1st, 2nd  or 3rd US 
3.7 (2.3-6.3) 57.4 79.1 33.8 90.5 
 




Predictive values of a score based on the presence or absence of the identified risk factors 
(prior pregnancy with macrosomia or GDM, maternal BMI ≥ 30 kg/m2) without or with 
inclusion of the fetal abdominal circumference ≥ 90th percentile as risk factor obtained by 1 or 
2 ultrasound examinations. In primiparae only maternal BMI and fetal AC were considered 
 
Cohort dived according to 
 No. of risk factors  
0 vs At least 1 RF 
Primiparae       Multiparae
0-1 vs At least 2 RF 
Primiparae       Multiparae 
0-2 vs at 
least 3 RF 
Score without US      
Spec  75.5 64.4  92.6  99.8 
Sens  39.5 64.0  23.6 8.7 
NPV  90.9 90.4  86.4 85.5 
PPV  23.8 25.1  37.5 90.0 
Score with 1st  US      
Spec 62.7 53.7 93.9 87.8 97.8 
Sens 61.7 77.2 23.5 44.7 15.8 
NPV 85.6 92.6 81.8 89.5 86.2 
PPV 30.8 23.6 51.6 40.5 58.1 
Score with 1st and 2nd US      
Spec 61.6 52.9 91.3 79.3 94.3 
Sens 63.7 78.0 36.2 59.6 28.1 
NPV 86.2 92.9 92.2 91.0 87.6 
PPV 30.8 23.6 55.8 34.1 47.8 
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4. Summary , discussion and perspectives 
 
 The standard management of pregnancies complicated by GDM is focused on the 
avoidance of maternal hyperglycemia. 1, 19, 79  Diet education and self-glucose-monitoring is 
recommended in all women. Insulin therapy is added if the glucose values of the daily profiles 
exceed a certain threshold. 19 There is strong evidence that in GDM pregnancies maternal, 
fetal and neonatal morbidity increases with increasing maternal hyperglycemia. 43, 80-83 
However, the relationship seems to behave in a continuous fashion 40, 41, 73, 74, 84, and 
diagnostic criteria for GDM as well as glycemic targets during pregnancy are rather based on 
expert opinion or consensus than on evidence. A great diversity exists regarding the criteria 
for the diagnosis of GDM. All threshold glucose values for the oral glucose tolerance test 
(oGTT) that had been used to define glucose intolerance are modifications of the original 
O’Sullivan criteria established in the early Sixties 21, and show a variation of up to 25 mg/dl 
for the post challenge glucose levels. 1, 19, 20, 85-87 Regarding glycemic control during 
pregnancy there is controversy if measurements at one hour postprandial are superior to the 
determination of two hour postprandial glucose values. 43, 88-90 The glucose targets show the 
same wide variation as the diagnostic criteria.  Overall, over the years the rate of adverse 
outcome in pregnancies with GDM had been reduced, and stillbirth is now rare in treated 
women with GDM. However, despite good glucose control the rate of neonatal morbidity is 
still elevated compared to pregnancies of women with normal glucose tolerance. 1, 73, 91-93 
The same phenomenon is seen in pregnancies of women with preexisting type 1 diabetes. 45, 
94 Some groups aimed to solve the dilemma by applying very tight glucose control to all 
women with GDM. This approach could reduce the rate of accelerated growth but resulted in 
insulin therapy and the demand of a high frequency of glucose monitoring in the majority of 
the women. 57-59 This strategy appears to be cost intensive and questionable with respect to 
the occurrence of morbidity only in a minority of cases and lacks evidence based data 
indicating the necessity of intensive treatment in all women.  
 The primary goal of the present work was to determine to what extent maternal 
glycemia in GDM pregnancies treated according to the standard management predicts 
neonatal morbidity. In a second step, we investigated whether inclusion of fetal growth 
patterns improves the neonatal outcome and provides an additional clinical tool for antenatal 
risk assessment. Our studies covered four major questions. Are maternal glucose values 
helpful to assess the risk for morbidity in early pregnancy of women with GDM? Are the 
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existing glucose criteria for diagnosis and treatment of GDM reliable to identify pregnancies 
at increased risk for diabetic morbidity? What are the major determinants of accelerated 
growth in treated GDM pregnancies? Are concepts of management based on fetal growth 
criteria save and what are the advantages compared to the standard approach?  
 
 It is well known since the early Sixties that preexisting type 1 diabetes is associated 
with an increased risk for congenital anomalies in the offspring and that the rate of 
malformations is positively correlated with the degree of maternal hyperglycemia at time of 
embryogenesis. 23, 24, 26, 27, 29, 33, 95, 96 Up to 1995, there was a paucity of data investigating 
the occurrence of congenital anomalies in GDM. Malformations had not been considered as a 
problem in GDM pregnancies since pregnancy induced glucose intolerance is supposed not to 
occur before the second trimester. Thus, we retrospectively investigated the rate and risk 
factors of congenital anomalies in a large cohort of 3700 women with hyperglycemia first 
detected in pregnancy (i.e. GDM) who attended the Diabetic Prenatal Care Clinic of the 
Women’s Hospital of the University of Southern California in Los Angeles. The fasting 
glucose value at time of diagnosis was the strongest predictor for major malformations and we 
identified a glucose level of 120 mg/dl as threshold of an increased risk for anomalies. 97 The 
rate of major anomalies increased from 2.1% to 5.2 % for fasting glucose levels between 120-
260 mg/dl. Interestingly, our identified threshold of 120 mg/dl corresponds to the glucose 
level in the first trimester previously identified for an increased risk for malformations in 
pregnancies with preexisting type 1 diabetes. 31 Furthermore, we investigated the pattern of 
congenital anomalies and their relationship to maternal fasting levels at diagnosis. We saw the 
same predominance of organ systems affected as in type 1 diabetes and a tight relation of the 
severity, i.e. the number of affected organ systems, and the level of fasting hyperglycemia. 98  
 Our findings were opposing the hypothesis that the physiologic decrease of glucose 
tolerance in pregnancy does reach a significant level far beyond embryogenesis. We were 
faced to the argument that a fair amount of the women in our population presumably had 
undiagnosed type 2 diabetes before pregnancy. The ethnic background of our predominantly 
Mexican-American women allows speculations about a high rate of undiagnosed type 2 
diabetes although a fasting of 120 mg/dl does not even fulfill the recently lowered criteria for 
diabetes outside pregnancy. 37 However, when we excluded women with persisting diabetes 
postpartum diagnosed by an oGTT 4-16 weeks postpartum, we still confirmed our results. 
Considering the course of the development of pregnancy induced glucose intolerance, the 
women presumably have had even lower glucose values in the first trimester. Another aspect 
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was the high rate of obesity in the study population that is common in women with GDM. 
Obesity and the associated hyperinsulinemia by itself is a risk factor for malformations.  99, 
100 Experimental studies demonstrated that diabetic embryopathy is associated with an excess 
of radical oxygen species. It had been shown that hyperglycemia leads to increased embryonic 
levels of the products of lipid peroxidation. 101 The physiologic increase of lipoxygenase 
activity is normally counterbalanced by an increase in the antioxidant system activity. 101, 102 
It might be that in obese women with increased number of adipocytes a lower degree of 
hyperglycemia is sufficient to disturb this counterbalance. For obstetrical clinical care during 
pregnancy, the speculation of an underlying undiagnosed type 2 diabetes is of minor 
relevance and per definition the diagnosis of GDM comprises a wide range of severity of 
glucose intolerance. 1  In conclusion, we could positively answer our question that maternal 
glucose values are helpful to assess the risk for morbidity in early pregnancy of women with 
GDM. High fasting glucose levels at diagnosis clearly indicate a risk for congenital 
malformations and should prompt an intensive specified fetal ultrasound examination. Our 
findings had been confirmed by recent studies. 103-106 
 
 In contrast to the obvious tight relation between maternal glucose values and 
embryonic morbidity in early pregnancy, we are faced with a different situation in the later 
course of pregnancy. The data of our studies indicate that neither the current diagnostic 
criteria nor the glucose values during therapy reliably predict neonatal morbidity. The 
diagnosis of GDM requires at least two pathologic glucose values independently of the 
applied criteria  - either O’Sullivan, Carpenter and Coustan, ADA or WHO. We investigated 
specific parameters of diabetic morbidity in pregnancies of women with only one elevated 
glucose value in the oGTT according to O’Sullivan criteria, defined as impaired glucose 
tolerance (IGT). The rate of elevated amniotic fluid insulin (> 7 µU/ml), hypoglycemia (< 30 
mg/dL), neonatal obesity, LGA and severe immaturity of the placenta was significantly higher 
in newborns of women with IGT compared to those from women with a normal oGTT. 73, 107 
Neonatal obesity was defined as the sum of skinfold thickness measurements obtained at three 
sites of the body above the 90th percentile of gender-specific percentile rankings which were 
previously determined by measurements of skinfolds in 250 consecutive newborns with 
gestational age > 37 weeks. Hyperinsulinism, hypoglycemia and neonatal obesity were 
virtually even more frequent in IGT than in treated GDM pregnancies.  
 We also confirmed the impact of borderline glucose intolerance in a study that was 
primarily designed to determine the incidence and timing of and risk factors for hypoglycemia 
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in large-for-gestational-age (LGA) newborns of non-diabetic mothers. Excessive fetal growth 
may indicate fetal hyperinsulinism that exposes the newborn at high risk of hypoglycemia 
when the glucose supply suddenly drops after delivery. Therefore, frequent glucose testing is 
recommended in LGA newborns. 108, 109 Hypoglycemia occurred in 16% of the infants and 
the only predictor for hypoglycemia was the 1-hour glucose value of the maternal antenatal 
oGTT. 110 A threshold glucose level of 180 mg/dl revealed to be a good discriminator for an 
increased risk of hypoglycemia. The incidence sharply rises to 25% compared to 2.5% for 1-
hour glucose value < 120 mg/dl and 9.3 % for 120-179 mg/dl. Interestingly, the glucose level 
of 180 mg/dL corresponds to the 1-hour glucose threshold of the Carpenter and Coustan 
criteria for the oGTT. 20 Thus, a majority of the mothers of newborns with high risk for 
hypoglycemia had untreated IGT.  
 Our observations of the impact of IGT on the neonatal outcome are in agreement with 
other studies using either one abnormal oGTT glucose value or increasing glucose values 
below the diagnostic criteria for GDM to define borderline glucose intolerance. 38-42, 92, 111 In 
contrast to these studies, we included highly specific parameters like amniotic fluid insulin 
that had not been investigated in IGT before. The data of others and our group reflect the 
major deficit of all currently applied criteria. They are all derived from the original O’Sullivan 
criteria that had been design to investigate the relation of antenatal oGTT values and the risk 
for maternal diabetes in later life.  They did not consider the risk for neonatal morbidity. The 
multicenter HAPO-study involving 25000 pregnancies has been started in the year 2000 
(HAPO= hyperglycemia adverse pregnancy outcome) to finally determine oGTT thresholds 
for short and long term morbidity of the offspring. 112 The results will not be available before 
2004/5. When currently available criteria were applied, based on our data the requirement of 
at least two pathologic values in the oGTT to initiate therapeutic intervention does not appear 
to be justified and should be reconsidered. The actual German guidelines for diagnosis and 
therapy of GDM reflect the impact of IGT and recommend diet education and glucose control 
similar to GDM pregnancies. 87 
 
 As mentioned before, good glycemic control during pregnancy according to the 
recommended glycemic goals is not able to normalize the morbidity rate in GDM 
pregnancies. In our own population, we could lower the macrosomia rate of 24% in the early 
Nineties 73 by the implementation of self-glucose monitoring in all women. However, the 
current rate is still about 18%. 89, 113  Thus, we retrospectively investigated the relation of 
maternal glucose values during the course of pregnancy and fetal growth pattern in a 
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population of 400 women with IGT or GDM. Since the fetal abdominal circumference (AC) 
is known to be a good predictor for LGA at birth 47, 55, 56  (own unpublished data 5.1), we 
have chosen a fetal AC < and ≥ 90th percentile to discriminate between pregnancies with 
normal and accelerated growth. 48 We compared pre-and postprandial glucose values of the 
daily profiles at 5 different periods of pregnancy with the AC measurements at corresponding 
gestational ages. There was no difference in glucose values between pregnancies with AC < 
and ≥ 90th percentile either at diagnosis or later in pregnancies, with the exception of the 
fasting glucose values between 32-35 weeks of gestation. In contrast, there was a tight 
relation to the maternal BMI. The rate of fetal AC ≥ 90th percentile and LGA at birth was 
significantly higher in women with BMI ≥ 30 kg/m2 compared to lean women (28% vs 14% 
at entry). 113  
 In a second step, we evaluated various parameters influencing fetal growth and 
determined independent predictors for an AC ≥ 90th percentile at diagnosis, during pregnancy 
and for LGA at birth. A history of LGA and obesity with BMI ≥ 30 kg/m2, either alone or 
combined, were independent predictors for an AC ≥ 90th percentile at entry, at 24-27 (history 
of LGA) and 28-31(both) weeks of gestation and for LGA at birth. In contrast, the fasting 
glucose at 32-35 weeks proved to be the only predictors at 32-35 and 36-40 weeks.  89 The 
identified predictors and the periods of their major influence on fetal growth reflect the 
primary impact of genetic and epigenetic factors in previous pregnancies (history of LGA) in 
the early third trimester (obesity), of recent maternal parameters in the mid third trimester and 
the influence of the stimulation of growth by elevated maternal glucose in the late third 
trimester. The majority of the women (> 90%) had good glucose control which might explain 
the limited influence of maternal glucose values. But this also implicates that tighter glucose 
control might not be efficient because of the strong contribution of other factors. e.g. maternal 
obesity. Maternal obesity is known to be an independent risk factor for macrosomia in 
pregnancies with impaired 114 as well as normal glucose tolerance 115-117 due to peripheral 
hyperinsulinism 118 and increased levels of serum lipids and amino acids in face of normal 
maternal glucose values. 50, 51 Macrosomic infants of obese mothers show the same 
disturbances in lipids profiles as their mothers 119 and the neonatal fat mass determines 43% 
of the variance in birth weight although it accounts only for 14% of the total body weight. 120, 
121  
 In conclusion, the existing glucose criteria for diagnosis and treatment of GDM do not 
appear to be reliable to identify pregnancies at increased risk for neonatal morbidity. Thus, a 
tailored management concept which considers the individual maternal conditions, might 
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improve the efficacy and outcome of care in GDM. In obese women, prepregnancy 
counseling about the adverse effects of obesity on pregnancy outcome and a moderate caloric 
restriction might reduce additional obesity associated morbidity. It was shown that a 33% 
caloric restriction lowers triglycerides without marked ketonuria. 122 However, the effect of 
interventions during pregnancy seems less promising than prepregnancy counseling since the 
majority of obese women demonstrate low weight gain in pregnancy.  
 
 The limited predictive ability of maternal glycemia for neonatal outcome is not only 
caused by the impact of maternal fuels besides glucose but also by the alterations in placental 
transport and consumption of fuels associated with diabetes, 123-125 and the individual 
susceptibility of the fetus to oversupply. 78, 126  Fetal-based management strategies aimed to 
avoid these uncertainties by concentrating directly on the target, the fetus. The measurement 
of fetal insulin was one approach established by Weiss. 65 The level of fetal insulin can be 
determined by amniotic fluid insulin (AF insulin) secondary to the urinary excretion of 
insulin. 68, 127 Diabetic fetopathy is causally related to fetal hyperinsulinism. 14, 44, 128 The 
Weiss approach directed intensive insulin therapy to women with elevated AF insulin levels 
without respect to maternal glycemia. The disadvantage of his strategy was that amniotic fluid 
is accessible only by an invasive amniocentesis. Another approach used fetal overgrowth 
identified by ultrasound as a clinical marker for presumed fetal hyperinsulinism 60-62 , and 
directed insulin therapy to pregnancies with an accelerated growth of the fetal AC. 
Determination of fetal growth is an indirect approach to assess hyperinsulinism and there was 
concern about over- or under-treatment when therapy is predominately based on fetal growth. 
Thus, we evaluated our data from amniocenteses in women with diabetes derived from times 
when determination of AF insulin was part of our routine management. We could demonstrate 
a weak but significant correlation between the fetal AC at time of amniocentesis and the level 
of AF insulin. Moderately elevated levels (90th percentile = 7 µU/ml) were poorly identified 
but a level of 16 µU/ml was excluded by an AC < 75th percentile with a negative predictive 
value of 100%. 129  Kainer et al 70, demonstrated similar results in a population consisting 
exclusively of women with type I diabetes. Interestingly, the identified AC threshold 
corresponds to the AC percentile that is used in the fetal-growth-based approach to initiate 
insulin therapy. The level of 16 µU/ml is still below the levels reported by other researchers to 
be associated with short 66, 71 and long term morbidity. 72 After establishing a correlation 
between the fetal AC and AF insulin we were additionally interested to determine the power 
of the AC to predict LGA at birth. Although an AC > 90th percentile at entry was the strongest 
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independent predictor, the predictive power of the ultrasound was only slightly higher than 
that of maternal history predictors like BMI, history of GDM or LGA. A second ultrasound 
slightly added to the predictive power (own unpublished data in 2.3.1) when evaluated in a 
single fashion. But when all predictors were combined for a score, the second ultrasound did 
not improve the predictive power. Similar to the predictive power for AF insulin, ultrasound 
seemed to be more helpful to exclude than to predict LGA at birth.  
 The utility of the fetal AC to guide metabolic therapy in women with GDM was first 
investigated in a pilot study by the group of Buchanan and Kjos from Los Angeles. Their 
study population was limited to women with glucose values that would not have prompted 
insulin therapy based on a standard guidelines. Insulin was given in pregnancies with a fetal 
AC ≥ 75th percentile diagnosed by a single ultrasound at entry to care. 60, 61 The macrosomia 
rate could be reduced by 3 fold compared to pregnancies with AC ≥ 75th percentile but no 
insulin therapy (13 vs 45%) and reached the level of pregnancies with AC < 75th percentile at 
entry. This first study addressed the question whether morbidity could be lowered by targeted 
intervention in pregnancies identified as high risk based on fetal growth. A second study was 
designed to investigate whether the ultrasound-based approach also allows to avoid intensive 
intervention, i.e. insulin therapy and intensive glucose monitoring, in pregnancies at low-risk 
despite maternal hyperglycemia that would have required insulin therapy. 62 Insulin was not 
given when the fetus did not demonstrate accelerated growth in serial ultrasound 
examinations during pregnancy. Women with severe hyperglycemia had been excluded. 
Indeed, insulin therapy could be avoided in 38% of the women in the ultrasound-guided group 
without adverse neonatal or maternal outcome. Both studies were performed in predominantly 
Mexican-American women who are genetically determined to have a high rate of insulin 
resistance and obesity that might have had an important impact on the results. Therefore the 
wide applicability of the therapy concept was questioned. However, we could confirm the 
benefit and safety of the fetal-growth-based approach in a Caucasian population of 200 
women included in a study in Berlin 135 .We combined the approaches of both pilot studies 
and included both women who presented euglycemia under diet therapy and those with 
hyperglycemia. We did not find any adverse outcome either in the mother or in the offspring 
in pregnancies guided predominately by fetal growth compared to those guided solely by 
maternal glycemia. When we divided the population according to the selection that was done 
in the two previous pilot studies, we found the same reduction of LGA rate in women with 
euglycemia but accelerated fetal growth and save of insulin therapy in women with 
hyperglycemia but normal fetal growth. In the ultrasound-guided group, maternal 
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hypoglycemia prompting clinical intervention occurred in no case when insulin therapy was 
applied based on accelerated growth despite maternal glucose levels below the standard 
thresholds for the initiation of insulin therapy. Maternal jeopardy by hypoglycemia had been a 
serious concern when we transferred the fetal-growth-based approach to a population with 
milder glucose intolerance than normally seen in Mexican-Americans. Insulin therapy was 
given exclusively based on a fetal AC ≥ 75th percentile. No women developed a level of 
severe hyperglycemia which was included as additional criteria for insulin therapy in the 
protocol.  
 
 Our studies in pregnancies complicated by GDM demonstrated that in women 
presenting high fasting glucose values at diagnosis the maternal glucose values are extremely 
reliable to assess the risk for disorders in embryogenesis resulting in congenital anomalies. In 
the majority of the women with GDM congenital malformation are not a concern. In the later 
course of pregnancy, maternal glucose values are of limited use to predict neonatal morbidity 
and a new management approach that is predominantly based on fetal growth instead of 
maternal glycemia showed promising results. Considering the knowledge about glucose 
metabolism in pregnancy and the numerous factors influencing the fetal development, we 
were not surprised about the low predictive power of maternal glucose values in treated GDM 
pregnancies. The normalization of maternal glucose values is indisputably beneficial for 
mother and offspring in pregnancies with a high level of hyperglycemia like in preexisting 
type 1 and 2 diabetes. However, the majority of women with GDM demonstrate only 
moderately elevated values. In these women, insulin therapy often results only in a reduction 
of fasting glucose values by 10 mg/dl or postprandial glucose by 20-30 mg/dl. There is 
evidence that the thresholds for the initiation of insulin therapy are still higher than the 
glucose values of the normal obstetrical population. Parretti et al77 reported a 1-hour 
postprandial glucose value of 114 mg/dl as 97th percentile even at 38 weeks of gestation. If we 
attempt to reach this level, we will end up with an unacceptable high rate of insulin use. No 
doubt that maternal glucose supply is an important factor but it is only one parameter in the 
whole cascade that determines the outcome. A management solely based on maternal 
glycemia does not consider other maternal fuels or characteristics, placental function and the 
individual susceptibility of the fetus for disturbances. Twin studies demonstrated impressively 
the occurrence of fetal hyperinsulinism in one and normal insulin values in the other fetus. 78 
These data support our clinical experience. We saw fetuses obviously presenting 
disproportional growth with an AC > 90th percentile and the mother had glucose values far 
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below the thresholds for insulin therapy 135. On the other side, we had normally grown fetuses 
with maternal glycemia that would require insulin therapy when we followed the 
recommendations. In extreme cases, we caused growth restriction. We had 6 small-for -
gestational-age (SGA) newborns in the standard group of the Berlin study when we had to 
give insulin in fetuses with normal AC (table 3, Box B, 6.1). Additionally we should keep in 
mind that we based our decision for insulin therapy on self-glucose-monitoring. This 
implicated considerable problems like the accuracy of reflectance meters, the individual 
technique of the women and an improved compliance in diet at days selected for glucose 
profiles.     
 Following critical data analysis and present knowledge it is obvious that an additional 
tool beside maternal glucose is needed to identify GDM pregnancies at risk for neonatal 
morbidity. Why do we not include the target - the fetus himself ? The approach based on the 
identification of fetal hyperinsulinism via measurement of amniotic fluid insulin presents the 
most reliable method but can not be widely recommended because of the requirement of an 
amniocentesis. However, the fetal-growth-based management uses a method to target GDM 
pregnancies with need for intensive intervention which is part of the routine in prenatal care. 
However, there are two concerns that should be addressed when we discuss the utility of this 
approach. First, the unsatisfying accuracy of ultrasound to predict birth weight or the 
development of LGA, especially in diabetic pregnancies 130 or extremely overweight fetuses. 
131 This is caused by the limitation of the technique itself combined with the individual 
capacities of the ultrasonographers and the high rate of obesity in GDM women. In fetuses 
with accelerated growth due to maternal diabetes, we are additionally faced with an increase 
in adipose tissue that is less dense than fat-free tissue, e.g. muscle and bone.  Thus the use of 
growth percentiles derived from an unselected patient population may lead to sonographic 
overestimation of fetal weight. 121, 132   This might explain our finding of a high false positive 
rate of the AC in predicting LGA babies which is consistent with the reports of others. 55, 56 
The specificity of the fetal AC to predict an LGA newborn was about 80% thus 20 of 100 
women would have been treated with insulin without having a fetus at risk. On the other side, 
data from Weiss showed that only 50% of the fetuses presented elevated insulin levels with a 
maternal mean blood glucose level of 100 mg/dl. 66 This mean glucose level corresponds to 
the recommended fasting and postprandial glucose levels for initiation of insulin therapy. 19 
Thus, using the standard glycemia-based approach 50 of 100 women are treated with insulin 
without having a fetus at risk. 
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 What are the perspectives in the care of women with GDM?  The increase of obesity 
in young women accompanied with a high risk for GDM will face us with rising numbers of 
women with GDM seeking care. Official surveys in Germany estimate a rate of 19% obese 
teenagers for 1995 which increased up to 32 % for the year 2000. 133, 134 Thus, we have to 
optimize the allocation of resources for treatment by targeting high-risk pregnancies for 
intensive intervention. Strict glucose control in all women without additional risk assessment 
might cause avoidable financial and emotional costs and will eventually consume valuable 
resources. The fetal-growth-based concept of care includes antenatal risk assessment and 
therefore might not only improve the efficacy of care but also help to improve cost-efficient 
treatment. In our study, almost 60% of the women in the ultrasound group identified to be at 
low-risk performed glucose profiles without clinical consequences. We neither discussed the 
values, nor were the women encouraged to observe their diet. They were not aware of the 
thresholds for insulin therapy. We can only speculate about the effect of self-glucose-
monitoring in these women since they could not be blinded to the numbers showing up on the 
reflectance meters. In future, we might be able to adjust the frequency and intensity of glucose 
control based on the risk assessment by fetal growth, resulting in a considerable reduction of 
monitoring in low-risk women.  Intensive glucose monitoring is the most cost intensive 
parameter in the diabetic management of GDM pregnancies and adds an unpleasant 
diagnostic technique for the mothers. In contrast, ultrasound is well accepted by the women 
and part of the routine prenatal care. Based on recent costs and diagnosis of GDM estimated 
at 28 weeks of gestation, the calculated expenses were 160 Euro for glucose monitoring 
consisting of 2 profiles per week and 220 Euro if 3 profiles would be performed. Our data 
indicate that 90% of the cases with AC > 75th percentile are diagnosed by a 1st or a 2nd 
ultrasound examination (unpublished data 6.1) and that a 3rd examination will add only little 
predictive power (unpublished data 5.1). When we assume 2 ultrasound examinations and e.g. 
2 profiles per month, we will end up with a total amount of 37 Euro. The first ultrasound does 
not add additional cost since one exam of fetal growth is part of the German prenatal care 
protocol. Thus, we estimate that our approach will cut down the costs for diabetic care in 
GDM by 4 or 6 fold, respectively. 
 
Our studies indicate that GDM therapy assignment based on fetal ultrasound 
assessment in addition to limited baseline maternal glycemic values is a safe, more pleasant 
and likely less cost intensive approach. Still, several topics need further investigations. We 
will have to determine to what extend glucose monitoring could be reduced in low-risk 
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pregnancies with moderately GDM without increasing risk of adverse neonatal and maternal 
outcome. Second, whether this strategy is not only safe but also represents a significant 
improvement of the outcome remains to be proven in larger cohorts. Last, the establishment 
of more specific, and easily reproducible sonographic measures of evolving diabetic fetopathy 
in utero as part of the routine ultrasound examination would further enhance the clinical value 
of involving fetal ultrasound.  
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AC    Fetal abdominal circumference 
ADA    American Diabetes Association 
AF insulin   Amniotic fluid insulin 
AGA    Appropriate-for gestational-age newborn 
FCG    Fasting capillary glucose 
GCT    Glucose Challenge test 
GDM    Gestational diabetes mellitus 
IGT    Impaired glucose tolerance 
OGTT    Oral glucose tolerance test 
LGA    Large-for-gestational newborn 
NDDG   National diabetes data group 
NPV    Negative predictive value 
NICU    Neonatal intensive care unit 
SGA    Small-for-gestational-age newborn 
Standard-group  Study group management by maternal glycemia 
US-group   Study group managed by criteria of fetal growth  
ROC curves   Receiver operator characteristics curves 
WHO    World Health Organization 
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